Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

This study is looking for people who have been diagnosed with Mycosis fungoides, which is a common type of CTCL, specifically in stages 1B, 2A, or 2B. To join, you must be at least 18 years old and have already tried at least one other treatment for your cancer that didn't work or where your cancer came back.

There are also some important health checks you'll need to pass. For example, your blood tests for things like your white blood cells, platelets, and liver and kidney function need to be within a healthy range. Any side effects you had from previous cancer treatments must have mostly cleared up, meaning they are mild or gone. Your heart also needs to be working well.

If you are a woman who could become pregnant, you'll need to have a negative pregnancy test before starting the study and agree to use effective birth control during the study and for 6 months after your last dose. Men who are able to have children will also need to use effective birth control with their partners during the study.

If you decide to take part in this study, you'll receive the study drug, mogamulizumab, and a special type of radiation therapy called Total Skin Electron Beam (TSEB). The study involves a specific sequence: you'll first receive mogamulizumab injections, then undergo TSEB radiation, and finally, continue with mogamulizumab injections as a maintenance treatment. You will have regular appointments for check-ups, blood tests, and to monitor your health and response to treatment. The total duration of the study treatment and follow-up will be discussed with you by the research team. You'll need to attend clinic visits for your treatments and to have various assessments to see how you're doing. The research team will explain the full schedule, including how often you'll need to visit and for how long.